Oxford BioMedica (OTCMKTS:OXBDF – Get Free Report) reached a new 52-week high on Friday . The company traded as high as $9.9850 and last traded at $9.9850, with a volume of 600 shares. The stock had previously closed at $9.50.
Oxford BioMedica Price Performance
The company has a debt-to-equity ratio of 3.08, a current ratio of 1.89 and a quick ratio of 1.67. The stock has a 50-day moving average price of $8.49 and a 200 day moving average price of $7.34.
Oxford BioMedica Company Profile
Oxford BioMedica is a clinical-stage gene and cell therapy company headquartered in Oxford, United Kingdom. The company specializes in the development, manufacturing and commercialization of lentiviral vector delivery systems for use in treating serious diseases. Its proprietary LentiVector® platform underpins both in-house development programs and third-party collaborations, enabling the stable integration of therapeutic genes into target cells.
In its research pipeline, Oxford BioMedica is advancing candidates across ophthalmology, neuroscience and oncology indications.
Read More
- Five stocks we like better than Oxford BioMedica
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- A U.S. “birthright” claim worth trillions – activated quietly
- Ticker Revealed: Pre-IPO Access to “Next Elon Musk” Company
- First Time Since 2007: All Warnings Active
- How the Rich Retire
Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png?v=20220915161652&h=45&w=95&zc=2){kind=logo}
